All AbMole products are for research use only, cannot be used for human consumption.
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity.
| CAS Number | 2066544-85-0 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Related Products |
|---|
| DSPE-PEG-FA
DSPE-PEG2K-FA is a PEG derivative containing folic acid. DSPE-PEG2K-FA has a targeting effect and can bind to folic acid receptors in cancer cells. DSPE-PEG2K-FA forms micelles/lipid bilayers and can be used in research on targeted drug delivery systems. |
| Lifastuzumab
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. |
| GPVI antagonist 1
GPVI antagonist 1 is a glycoprotein VI (GPVI) platelet receptor antagonist. GPVI antagonist 1 inhibits collagen-induced platelet aggregation with an IC50 of 25.3 μM. |
| MPSD TFA
MPSD TFA (MARCKS-ED TFA) is a 25-amino acid peptide based on the effector domain sequence of the intracellular membrane protein myristoylated alanine-rich C-kinase substrate (MARCKS). MPSD TFA can sense membrane curvature and recognize phosphatidylserine. MPSD TFA can be utilized as biological probe to study membrane shape and lipid composition. |
| 4-Nitro-2,1,3-benzoselenadiazole
4-Nitro-2,1,3-benzoselenadiazole is a biochemical material that can be used in scientific research. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
